Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib

被引：14
|
作者：
Yagi, Kumi [1 ]
Ishida, Yoshihiro [1 ]
Otsuka, Atsushi [1 ]
Kabashima, Kenji [1 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷 / 03期
关键词：
D O I：
10.1111/ajd.13572
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：433 / +
页数：2
相关论文
共 50 条
  • [21] Repigmentation in non-segmental vitiligo using the Janus kinase inhibitor upadacitinib, a retrospective case series
    Zhu, Jing
    Luo, Lingling
    Guo, Youming
    Wei, Tianqi
    Huang, Xin
    Xiao, Xuemin
    Li, Chengrang
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 317 (01)
  • [22] Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo
    Hayashi, Masahiro
    Okamura, Ken
    Abe, Yuko
    Hozumi, Yutaka
    Suzuki, Tamio
    JOURNAL OF DERMATOLOGY, 2019, 46 (06): : 548 - 550
  • [23] Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
    Powers, Camille M.
    Verma, Hannah
    Orloff, Jeremy
    Piontkowski, Austin J.
    Tiersten, Amy
    Lamb, Angela
    Gulati, Nicholas
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [24] Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib
    Blechman, Adam B.
    Cabell, Christine E.
    Weinberger, Christine H.
    Duckworth, Anna
    Leitenberger, Justin J.
    Zwald, Fiona O.
    Russell, Mark A.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (05) : 508 - 511
  • [25] Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
    Asou, Mea
    Asakawa, Tomohiko
    Araki, Makoto
    Ehara, Takashi
    Hishima, Tsunekazu
    Sakamaki, Hisashi
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2021, 11 (01): : 1 - 9
  • [26] Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: A phase II, randomized, double-blind, vehicle-controlled study
    Nakagawa, Hidemi
    Nemoto, Osamu
    Igarashi, Atsuyuki
    Saeki, Hidehisa
    Kabashima, Kenji
    Oda, Manabu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB53 - AB53
  • [27] Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
    Joshipura, Deep
    Alomran, Abdulaziz
    Zancanaro, Pedro
    Rosmarin, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (06) : 1205 - +
  • [28] Cutaneous lichen planus successfully treated with the Janus kinase-1 inhibitor, abrocitinib
    Wang, Xi
    Wang, Yue
    Fang, Haoyue
    Lin, Mengbi
    Wang, Fuxi
    Zhang, Si
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (05) : 557 - 559
  • [29] Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib
    Xiao, Yue
    Xiang, Hongmei
    Li, Wei
    DERMATOLOGIC THERAPY, 2022, 35 (10)
  • [30] Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases
    Wendel, Sarah
    Venhoff, Nils
    Frye, Bjoern C.
    May, Annette M.
    Agarwal, Prerana
    Rizzi, Marta
    Voll, Reinhard E.
    Thiel, Jens
    JOURNAL OF AUTOIMMUNITY, 2019, 100 : 131 - 136
12345